Mécasermine (Increlex) et risque de tumeur bénigne ou maligne : extension de la contre-indication - Point d'information ANSM (05/03/2020)
Powered by
eZ Publish™ CMS Open Source Web Content Management
. Copyright © 1999-2014
eZ Systems AS
(except where otherwise noted). All rights reserved.